Skip to Content

UK Edition. Click here for US version.

TEVA LISINOPRIL AND HYDROCHLOROTHIAZIDE 20MG/12.5MG TABLETS

Active substance(s): HYDROCHLOROTHIAZIDE / LISINOPRIL DIHYDRATE

PDF options:  View Fullscreen   Download PDF

PDF Transcript

SUMMARY OF PRODUCT CHARACTERISTICS

1

NAME OF THE MEDICINAL PRODUCT
Teva Lisinopril and Hydrochlorothiazide 20 mg/12.5 mg Tablets

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Tablet
White oval shaped, slightly arched tablets, debossed “LZ 20” on one side and
breakline on the other.
The score line is only to facilitate breaking for ease of swallowing and not to divide
into equal doses.

3

PHARMACEUTICAL FORM
Each tablet contains lisinopril dihydrate equivalent to lisinopril 20 mg and
hydrochlorothiazide 12.5 mg.
For full list of excipients, see section 6.1.

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
Treatment of essential hypertension.
Lisinopril/hydrochlorothiazide fixed dose combination (20 mg lisinopril and 12.5 mg
hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately
controlled on lisinopril alone (or hydrochlorothiazide alone).

4.2

Posology and method of administration
The selection of a suitable antihypertensive dose of lisinopril and hydrochlorothiazide
will depend upon the clinical evaluation of the patient.
Lisinopril/hydrochlorothiazide should be taken once daily.
The administration of the fixed combination lisinopril and hydrochlorothiazide is
usually recommended after dosage titration with the individual components.

When clinically appropriate, a direct change from monotherapy to fixed combination
may be considered.
20 mg/12.5 mg tablets may be administrated in patients whose blood pressure is not
adequately controlled by 20 mg lisinopril alone.
A maximum daily dose of 40 mg lisinopril/ 25 mg hydrochlorothiazide should not be
exceeded.
Diuretic Pretreatment
The diuretic therapy should be stopped two to three days prior to the start of a
treatment with lisinopril/hydrochlorothiazide. If this is not possible, treatment should
be started with lisinopril alone, in a 2.5 mg dose.
Special populations
Renal impairment
The combination lisinopril/hydrochlorothiazide is contraindicated in patients with
severe renal impairment (creatinine clearance <30 ml/min). In patients with creatinine
clearance between 30 and 80 ml/min it may be used only after titration of the
individual components.
The recommended initial dose of lisinopril as monotherapy for these patients is 5-10
mg (see section 4.4).
Older people
Clinical studies on the combination of lisinopril and hydrochlorothiazide have not
shown that age is associated with any changes in efficacy or tolerability. See the
above section on “Renal impairment”.
Paediatric population
Safety and efficacy of lisinopril/hydrochlorothiazide have not been established in
children.

4.3

Contraindications

Hhypersensitivity to the active substance , any other angiotenzin converting
enzyme ACE- inhibitors or to any of the excipients listed in section 6.1.

Hypersensitivity to hydrochlorothiazide or other sulphonamide medicinal products

History of angioedema relating to previous ACE-inhibitor therapy

Hereditary or idiopathic angioedema.

Severe renal impairment (creatinine clearance <30 ml/min)

Anuria

Severe hepatic impairment

Second and third trimesters of pregnancy (see sections 4.4 and 4.6).

The concomitant use of Teva Lisinopril and Hydrochlorothiazide 20/12.5 mg Tablets
with aliskiren-containing products is contraindicated in patients with diabetes mellitus or
renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).


4.4

Special warnings and precautions for use

Lisinopril
Symptomatic hypotension
Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients. In
hypertensive patients receiving lisinopril, hypotension is more likely to occur if the patient
has been volume-depleted e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea
or vomiting, or has severe renin-dependent hypertension (see sections 4.5 and 4.8). In patients
with heart failure, with or without associated renal insufficiency, symptomatic hypotension
has been observed. This is most likely to occur in those patients with more severe degrees of
heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia or
functional renal impairment. Regular determination of serum electrolytes should be
performed at appropriate intervals in such patients. In patients at increased risk of
symptomatic hypotension, initiation of therapy and dose adjustment should be monitored
under close medical supervision. Particular considerations applies to patients with ischaemic
heart or cerebrovascular disease because an excessive fall in blood pressure could result in
myocardial infarction or a cerebrovascular accident.
If hypotension occurs, the patient should be placed in the supine position and, if necessary,
should receive an intravenous infusion of normal saline. A transient hypotensive response is
not a contraindication to further doses, Following restoration of effective blood volume and
pressure, reinstitution of therapy at reduced dosage may be possible; or either of the
components may be used appropriately
In some patients with heart failure who have normal or low blood pressure, additional
lowering of systemic blood pressure may occur with lisinopril. This effect is anticipated and
is not usually a reason to discontinue treatment. If hypotension becomes symptomatic, a
reduction of dose or discontinuation of lisinopril may be necessary.
Aortic and mitral valve stenosis / hypertrophic cardiomyopathy
As with other ACE inhibitors, lisinopril should be given with caution to patients with mitral
valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or
hypertrophic cardiomyopathy.
Renal function impairment
See section 4.2.
In patients with heart failure, hypotension following the initiation of therapy with ACE
inhibitors may lead to some further impairment in renal function. Acute renal failure, usually
reversible, has been reported in this situation.
In some patients with bilateral renal artery stenosis or with a stenosis of the artery to a solitary
kidney, who have been treated with ACE inhibitors, increases in blood urea and serum
creatinine, usually reversible upon discontinuation of therapy, have been seen. This is
especially likely in patients with renal insufficiency. If renovascular hypertension is also
present there is an increased risk of severe hypotension and renal insufficiency. In these
patients, treatment should be started under close medical supervision with low doses and
careful dose titration. Since treatment with diuretics may be a contributory factor to the above,
they should be discontinued and renal function should be monitored during the first weeks of
lisinopril therapy.
Some hypertensive patients with no apparent pre-existing renal disease have developed
increases in blood urea and serum creatinine, usually minor and transient, especially when
lisinopril has been given concomitantly with a diuretic. This is more likely to occur in patients
with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic
and/or lisinopril may be required.
Patients with renal transplantation
Should not be used, since there is no experience with lisinopril in patients with recent renal
transplantation.
Hypersensitivity/angioedema

Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported
rarely in patients treated with angiotensin converting enzyme inhibitors, including lisinopril.
This may occur at any time during therapy. In such cases, lisinopril should be discontinued
promptly and appropriate treatment and monitoring should be instituted to ensure complete
resolution of symptoms prior to dismissing the patients. Even in those instances where
swelling of only the tongue is involved, without respiratory distress, patients may require
prolonged observation since treatment with antihistamines and corticosteroids may not be
sufficient.
Very rarely, fatalities have been reported due to angioedema associated with laryngeal
oedema or tongue oedema. Patients with involvement of the tongue, glottis or larynx, are
likely to experience airway obstruction, especially those with a history of airway surgery. In
such cases emergency therapy should be administered promptly. This may include the
administration of adrenaline and/or the maintenance of a patent airway. The patient should be
under close medical supervision until complete and sustained resolution of symptoms has
occurred.
Angiotensin converting enzyme inhibitors cause a higher rate of angioedema in black patients
than in non-black patients.
Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased
risk of angioedema while receiving an ACE inhibitor (see 4.3).
Concomitant use of mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus)
Patients taking concomitant mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus)
therapy may be at increased risk for angioedema (e.g. swelling of the airways or tongue, with
or without respiratory impairment) (see section ”Interaction with other medicinal products
and other forms of interaction”).

Anaphylactoid reactions in haemodialysis patients
The use of lisinopril-hydrochlorothiazide is not indicated in patients requiring dialysis for
renal failure. Anaphylactoid reactions have been reported in patients undergoing certain
haemodialysis procedures (e.g. with the high-flux membranes AN 69 and during low-density
lipoproteins (LDL) apheresis with dextran sulphate) and treated concomitantly with an ACE
inhibitor. In these patients consideration should be given to using a different type of dialysis
membrane or different class of antihypertensive agent.
Anaphylactoid reactions during low-density lipoprotein (LDL) apheresis
In rare occasions, patients receiving ACE inhibitors during low-density lipoprotein (LDL)
apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions.
These symptoms could be avoided by temporarily discontinuation of the treatment with ACE
inhibitor before each apheresis.
Desensitisation
Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom)
have sustained anaphylactoid reactions. In the same patients, these reactions have been
avoided when ACE inhibitors were temporarily withheld but they have reappeared upon
inadvertent re-administration of the medicinal product.
Hepatic disease
Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic
jaundice or hepatitis and progresses to fulminant necrosis and (sometimes) death. The
mechanism of this syndrome is not understood. Patients receiving lisinopril-

hydrochlorothiazide who develop jaundice or marked elevations of hepatic enzymes should
discontinue lisinopril/hydrochlorothiazide and receive appropriate medical follow-up.
Neutropenia/agranulocytosis
Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients
receiving ACE inhibitors. In patients with normal renal function and no other complicating
factors, neutropenia occurs rarely. Neutropenia and agranulocytosis are reversible after
discontinuation of the ACE inhibitor. Lisinopril should be used with extreme caution in
patients with collagen vascular disease, immunosuppressant therapy, treatment with
allopurinol or procainamide, or a combination of these complicating factors, especially if
there is pre-existing impaired renal function. Some of these patients developed serious
infections, which in a few instances did not respond to intensive antibiotic therapy. If
lisinopril is used in such patients, periodic monitoring of white blood cell counts is advised
and patients should be instructed to report any sign of infection.
Race
ACE inhibitors cause a higher rate of angioedema in black patients than in non-black patients.
As with other ACE inhibitors, lisinopril may be less effective in lowering blood pressure in
black patients than in non-blacks, possibly because of a higher prevalence of low-renin states
in the black hypertensive population.
Cough
Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is nonproductive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced
cough should be considered as part of the differential diagnosis of cough.
Surgery/anaesthesia
In patients undergoing major surgery or during anaesthesia with agents that produce
hypotension, lisinopril may block angiotensin II formation secondary to compensatory renin
release. If hypotension occurs and is considered to be due to this mechanism, it can be
corrected by volume expansion.
Hyperkalaemia
Elevations in serum potassium have been observed in some patients treated with ACE
inhibitors, including lisinopril. Patients at risk for the development of hyperkalaemia include
those with renal insufficiency, diabetes mellitus, hypoaldosteronism or those using
concomitant potassium-sparing diuretics, potassium supplements or potassium-containing salt
substitutes, or those patients taking other drugs associated with increases in serum potassium
(e.g. heparin, co-trimoxazole also known as trimethoprim/sulfamethoxazole). If concomitant
use of the above-mentioned agents is deemed appropriate, regular monitoring of serum
potassium is recommended (see section 4.5).
Diabetic patients
In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should
be closely monitored during the first month of treatment with an ACE inhibitor (see section
4.5).
Lithium
The combination of lithium and lisinopril is generally not recommended (see section 4.5).
Pregnancy
ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor
therapy is considered essential, patients planning pregnancy should be changed to alternative
antihypertensive treatments which have an established safety profile for use in pregnancy.

When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately,
and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).
Dual blockade of the renin-angiotensin-aldosterone system (RAAS)
There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers
or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function
(including acute renal failure). Dual blockade of RAAS through the combined use of ACEinhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see
sections 4.5 and 5.1).
If dual blockade therapy is considered absolutely necessary, this should only occur under
specialist supervision and subject to frequent close monitoring of renal function, electrolytes
and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used
concomitantly in patients with diabetic nephropathy.
Hydrochlorothiazide
Impaired renal function
In patients with renal diseases, thiazides may precipitate azotemia. In patients with impaired
renal function, cumulative effects of the medicinal products may occur. If progressive renal
insufficiency develops, characterized by an increase in non-protein nitrogen, careful
evaluation of the therapy is necessary, and stopping the diuretics therapy should be considered
(see section 4.3).
Impaired liver function
Thiazides should be used with caution in patients with impaired hepatic function or liver
disease, since minor alterations of fluid and electrolyte balance may induce hepatic coma (see
section 4.3).
Metabolic and endocrine effects
Thiazide therapy may impair glucose tolerance.Dosage adjustments of antidiabetic agents or
insulin drugs may be required. Latent diabetic mellitus may become manifest during thiazide
therapy.
Increases of cholesterol and triglyceride levels have been associated with thiazide diuretic
therapy. Thiazide therapy may precipitate hyperuricaemia and/or gout in certain patients
Electrolyte imbalances
As for any patient treated with diuretics, periodic determination of serum electrolytes at
appropriate intervals should be performed.
Thiazides, including hydrochlorothiazide, may cause fluid and electrolyte imbalances
(hypokalaemia, hyponatraemia and hypochloremic alkalosis). Warning signals of fluid or
electrolyte imbalances are dryness of mouth, thirst, weakness, lethargy, drowsiness,
restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia and
gastrointestinal disorders such as nausea and vomiting. Dilutional hyponatraemia may occur
in oedematous patients in hot weather. Chloride deficit is generally mild and does not require
treatment. Thiazides have been shown to increase the urinary excretions of magnesium, which
may result in hypomagnesaemia.
Although hypokalaemia may develop through the use of thiazide diuretics, concomitant use of
lisinopril may decrease diuretic-induced hypokalaemia. The possibility of hypokalaemia is
strongest in liver cirrhosis patients, in patients experiencing rapid diuresis, in patients having
an inadequate oral intake of electrolytes and in patients concomitantly treated with
corticosteroids or ACTH (see section 4.5).
Thiazides may decrease urinary calcium excretion and may cause a slight elevation of serum
calcium levels even in the absence of known disorders of calcium metabolism. Marked
hypercalcemia may evidence of hidden hyperparathyroidism. Thiazides should be
discontinued before carrying out parathyroid function tests.

Anti-doping test
The hydrochlorothiazide contained in this medication could produce a positive analytic result
in an anti-doping tests.
Other
In patients receiving thiazides, hypersensitivity reactions may occur with or without a history
of allergy or bronchial asthma.Exacerbation or activation of systemic lupus erythematosus has
been reported with the use of thiazides.
Lisinopril/hydrochlorothiazide
Hypotension and electrolyte/fluid imbalances
Symptomatic hypotension may sometimes occur following the first dose of lisinopril /
hydrochlorothiazide. The odds for hypotension in hypertensive patients are greater in the
presence of fluid or electrolyte imbalances, such as volume depletion, hyponatraemia,
hypochloremic alkalosis, hypomagnesemia or hypokalaemia, that may occur as a result of a
diuretic therapy, a low-sodium diet, dialysis or during intercurrent diarrhoea or vomiting. In
such patients the serum electrolyte levels must be monitored on a regular basis.
Starting the therapy and adjusting the dosage for patients who are at increased risk for
symptomatic hypotension must be done under strict medical supervision.
Special attention should be given to the treatment of patients suffering from ischaemic heart
disease or cerebrovascular conditions, because an excessive drop in blood pressure may
trigger a myocardial infarction or cerebrovascular accident.
If severe hypotension occurs, the patient must be put into the shock position and promptly
administered an intravenous infusion of a physiological saline solution. A transient
hypotensive reaction is not a contraindication for future doses. If the blood volume and blood
pressure have effectively been restored, therapy may likely be resumed with a lower dosage
or may very well be continued simply with one of both components.
As with other vasodilators, caution must be exercised when administering lisinopril /
hydrochlorothiazide to patients suffering from aortic stenosis or hypertrophic
cardiomyopathy.
Impaired renal function
Thiazides are ineffective in patients with a creatinine clearance of less than 30 ml/min (i.e. a
moderate or serious renal insufficiency) (see section 4.3).
Lisinopril/hydrochlorthiazide should not be given to patients with a creatinine clearance of
30-80 ml/minute until dose adjustments of the separate ingredients have shown that there is a
need for the doses in the combination preparation.
Some patients without a definite pre-existing renovascular disorder developed slight and
transitory increases in blood urea levels and serum creatinine levels when lisinopril was given
concomitantly with a diuretic. If this occurs during the use of lisinopril/ hydrochlorothiazide,
the treatment should be stopped. Resuming the treatment at a reduced dosage may be
possible, if appropriate, one of the components may be used on its own.
Prior diuretic therapy
The diuretic therapy should be discontinued for 2-3 days prior to initiation with lisinoprilhydrochlorothiazide. If this is not possible, treatment should be started with lisinopril alone, in
a 5 mg dose.
Risk of hypokalaemia
The combination of an ACE-inhibitor with a thiazide does not exclude the occurrence of
hypokalaemia. Regular checks of potassium should take place.
Neutropenia/agranulocytosis

The fixed-dose combination of lisinopril and hydrochlorothiazide should be withdrawn if
neutropenia (neutrophils less than 1000/mm3) is detected or suspected.

4.5

Interaction with other medicinal products and other forms of interaction
The following interactions between lisinopril/ hydrochlorthiazide tablets, other ACEinhibitors or products containing hydrochlorothiazide have been reported.
Lisinopril
Dual blockade of the renin-angiotensin-aldosterone system
Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone
system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor
blockers or aliskiren is associated with a higher frequency of adverse events such as
hypotension, hyperkalaemia and decreased renal function (including acute renal
failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and
5.1).
Diuretics
When a diuretic is added to the therapy of a patient receiving lisinopril, the
antihypertensive effect is usually additive.
Patients already on diuretics and especially those in whom diuretic therapy was
recently instituted, may occasionally experience an excessive reduction of blood
pressure when lisinopril is added. The possibility of symptomatic hypotension with
lisinopril can be minimised by discontinuing the diuretic prior to initiation of
treatment with lisinopril (see section 4.4).
Non steroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic acid =
3g/day
Chronic administration of NSAIDs (including selective cyclooxygenase-2 inhibitors)
may reduce the antihypertensive effect of an ACE inhibitor. NSAIDs and ACE
inhibitors may exert an additive effect on the increase in serum potassium and may
result in a deterioration of renal function. These effects are usually reversible. Rarely,
acute renal failure may occur, especially in patients with compromised renal function
such as the elderly or dehydrated.
Gold
Nitritoid reactions (symptoms of vasodilatation including flushing, nausea, dizziness
and hypotension, which can be very severe) following injectable gold (for example,
sodium aurothiomalate) have been reported more frequently in patients receiving
ACE inhibitor therapy.
Other antihypertensive medicinal products
Concomitant use of these medicinal products may increase the hypotensive effects of
lisinopril. Concomitant use with glyceryl trinitrate and other nitrates, or other
vasodilators, may further reduce blood pressure.
Tricyclic antidepressants/antipsychotics/anaesthetics

Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants
and antipsychotics with ACE inhibitors may result in further reduction of blood
pressure (see section 4.4).
Sympathomimetics
Sympathomimetics may reduce the hypotensive effect of ACE-inhibitors; patients
must be monitored carefully.
Antidiabetics
Epidemiological studies have suggested that concomitant administration of ACE
inhibitors and antidiabetic medicinal products (insulins, oral hypoglycaemic agents)
may cause an increased blood glucose-lowering effect with risk of hypoglycaemia.
This phenomenon appeared to be more likely to occur during the first weeks of
combined treatment and in patients with renal impairment.
Nitrates, acetylsalicylic acid, thrombolytics and/or beta blockers
Lisinopril may be used concomitantly with acetylsalicylic acid (cardiological doses),
thrombolytics, beta blockers and/or nitrates.
Allopurinol
Concomitant administration of ACE inhibitors and allopurinol increases the risk of
renal failure and may lead to an increased risk of leucopenia.
Ciclosporin
Concomitant administration of ACE inhibitors and ciclosporin increases the risk of
renal failure and hyperkalaemia.
Lovastatin
Concomitant administration of ACE inhibitors and lovastatin increases the risk of
hyperkalaemia.
Procainamide, cytostatics immunosuppressives
Concomitant administration with ACE inhibitors may lead to an increased risk of
leucopenia (see section 4.4)..
Haemodialysis
Lisinopril/hydrochlorothiazide is not indicated in patients requiring dialysis as a high
incidence of anaphylactoid reactions have been reported in patients dialysed with
high-flux membranes and treated concomitantly with an ACE inhibitor. This
combination should be avoided.
mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus)

Patients taking concomitant mTOR inhibitors therapy may be at increased risk for
angioedema (see section 4.4).
Co-trimoxazole (trimethoprim/sulfamethoxazole)
Patients taking concomitant co-trimoxazole (trimethoprim/sulfamethoxazole) may be
at increased risk for hyperkalaemia (see section 4.4).
Hydrochlorothiazide
Amphotericin B (parenteral), carbenoxolone, corticosteroids, corticotropine (ACTH)
or stimulating laxatives
Hydrochlorothiazide may cause electrolyte imbalances, especially hypokalaemia.
Calcium salts
Increased serum calcium levels as a result of decreased excretion may occur if
concomitantly administered with thiazide diuretics.
Cardiac glycosides
There is increased risk of digitalis intoxication together with thiazide induced
hypokalaemia.
Cholestyramine resin and colestipol
These may delay or reduce the absorption of hydrochlorothiazide. Therefore,
sulphonamide diuretics should be taken at least 1 hour before or 4 – 6 hours after
intake of these agents..
Non-depolarizing muscle relaxants (i.e. tubocurarine chloride)
The effect of these medications may be potentiated by hydrochlorothiazide.
Torsades de pointes- inducing medicinal products
Because of the risk of hypokalaemia, the concomitant administration of
hydrochlorothiazide and medicinal products that induce torsades de pointes, e.g. some
antiarrythmias, some antipsychotics and other drugs known to induce torsades de
pointes should be used with caution..
Sotalol
Thiazide-induced hypokalaemia can increase the risk of sotalol-induced arrhythmias.
Lisinopril/hydrochlorothiazide
Potassium supplements, potassium-sparing diuretics or potassium-containing salt
substitutes

Although in clinical trials with ACE inhibitors serum potassium usually remained
within normal limits, hyperkalaemia did occur in some patients. Risk factors for the
development of hyperkalaemia include renal insufficiency, diabetes mellitus, and
concomitant use of potassium-sparing diuretics (e.g. spironolactone, triamterene or
amiloride), potassium supplements or potassium-containing salt substitutes. The use
of potassium supplements, potassium-sparing diuretics or potassium-containing salt
substitutes, particularly in patients with impaired renal function, may lead to a
significant increase in serum potassium.
If lisinopril is given with a potassium-losing diuretic, diuretic-induced hypokalaemia
may be ameliorated.
If concomitant use of lisinopril-hydrochlorothiazide and any of these agents is
required, they should be used with caution and with frequent monitoring of serum
potassium (see section 4.4).
Lithium
Reversible increases in serum lithium concentrations and toxicity have been reported
during concomitant administration of lithium with ACE inhibitors. Concomitant use
of thiazide diuretics may increase the risk of lithium toxicity and enhance the already
increased lithium toxicity with ACE inhibitors. Use of lisinopril with lithium is not
recommended, but if the combination proves necessary, careful monitoring of serum
lithium levels should be performed (see section 4.4).
Trimethoprim
Concomitant administration of ACE inhibitors and thiazides with trimethoprim
increases the risk of hyperkaleamia.

4.6

Fertility, pregnancy and lactation

Pregnancy
ACE inhibitors:
The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see
section 4.4). The use of ACE inhibitors is contraindicated during the second and third
trimester of pregnancy (see sections 4.3 and 4.4).
Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE
inhibitors during the first trimester of pregnancy has not been conclusive; however a small
increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered
essential, patients planning pregnancy should be changed to alternative antihypertensive
treatments which have an established safety profile for use in pregnancy. When pregnancy is
diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate,
alternative therapy should be started.
Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce
human foetotoxicity (decreased renal function, oligohydramnios, skull ossification

retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section
5.3) Should exposure to ACE inhibitor have occurred from the second trimester of pregnancy,
ultrasound check of renal function and skull is recommended. Infants whose mothers have
taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).
Lisinopril, which crosses the placenta, has been removed from the neonatal circulation by
peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange
transfusion.
Hydrochlorothiazide
.There is limited experience with hydrochlorothiazide during pregnancy, especially during the
first trimester. Animal studies are insufficient.
Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of
action of hydrochlorothiazide its use during the second and third trimester may compromise
foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance
of electrolyte balance and thrombocytopenia.
Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or
preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion,
without a beneficial effect on the course of the disease.
Hydrochlorothiazide should not be used for essential hypertension in pregnant women except
in rare situations where no other treatment could be used.

Breast-feeding
ACE inhibitors:
Because no information is available regarding the use of Teva Lisinopril and
Hydrochlorothiazide 20mg/12.5mg Tablets during breast-feeding, Teva Lisinopril and
Hydrochlorothiazide 20mg/12.5mg Tablets is not recommended and alternative treatments
with better established safety profiles during breast-feeding are preferable, especially while
nursing a newborn or preterm infant.
Hydrochlorothiazide
Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses
causing intense diuresis can inhibit the milk production. The use of Teva Lisinopril and
Hydrochlorthiazide 20mg/12.5mg Tablets during breast-feeding is not recommended. If Teva
Lisinopril and Hydrochlorthiazide 20mg/12.5mg Tablets is used during breast-feeding, doses
should be kept as low as possible. Hypersensivity to sulphonamide-derived drugs,
hypokalaemia and nuclear icterus have also been observed.

4.7

Effects on ability to drive and use machines

As with other antihypertensives, lisinopril-hydrochlorothiazide combination products may
have a mild to moderate effect on the ability to drive and use machines. Especially.at the start
of the treatment or when the dose is modified, and also when used in combination with
alcohol, but these effects depend on the individual's susceptibility.

When driving vehicles or operating machines it should be taken into account that occasionally
dizziness or tiredness may occur.

4.8

Undesirable effects

Clinical studies have shown that the undesirable effects of the combination preparation are
similar to the ones already reported with lisinopril and hydrochlorothiazide separately.
The following undesirable effects have been observed and reported during treatment with
lisinopril and/or hydrochlorothiazide with the following frequencies: very common (>1/10),
common (>1/100,<1/10), uncommon (>1/1000,<1/100), rare (>1/10000,1/1000), very rare
(<1/10000) including isolated reports.
The most commonly reported ADRs are cough, dizziness, hypotension, and headache which
may occur in 1 to 10% of treated patients. In clinical studies, side effects have usually been
mild and transient, and in most instances have not required interruption of therapy.
Metabolism and nutrition disorders
uncommon: gout
Nervous system and psychiatric disorders
common: dizziness, which generally responded to dosage reduction and seldom required
discontinuation of therapy; headache, fatigue.
uncommon: paraesthesia, asthenia
Respiratory, thoracic and mediastinal disorders
common: dry and persistent cough, which disappeared after discontinuation of therapy.
Cardiac and vascular disorders
common: hypotension including orthostatic hypotension.
uncommon: palpitation, chest pain, muscle spasms and muscle weakness
Gastrointestinal disorders
uncommon: diarrhoea, nausea, vomiting, indigestion, pancreatitis, dry mouth.
Skin and subcutaneous tissue disorders
uncommon: rash.
rare: angioneurotic oedema of the face, extremities, lips, tongue, glottis and/or larynx (see
section 4.4)
Reproductive system and genitals and breast disorders
uncommon: impotence.
Others
rare: a complex of symptoms, consisting of one or more of the following: fever, vasculitis,
myalgia, artralgia or arthritis, positive ANA test; increased ESR, eosinophilia, leukocytosis,
rash, photosensibility or other dermatological manifestations.
Laboratory test values
Fluctuations in laboratory values were rarely of clinical importance. Hyperglycaemia,
hyperuricaemia, hyperkalemia or hypokalaemia have been reported incidentally. Increases in
blood cholesterol and triglyceride concentrations may be observed in thiazide treatment. A
slight increase in blood urea level and serum creatinine are usually found in patients without a

history of decreased renal function. When an increase is observed, this will usually disappear
after stopping the treatment. Bone marrow depression, which manifests itself as anaemia
and/or thrombocytopenia and/or leucopenia, has been reported. Agranulocytosis is reported in
rare cases, but a clear relation to the combination preparation could not be determined. Small
decreases in haemoglobin and haematocrit values are frequently reported in patients with
hypertension, but were rarely of clinical significance unless other anaemia causes existed.
Increases in liver enzymes and/or serum bilirubin have been noted rarely, but a causal link to
lisinopril/hydrochorothiazide has not been determined.
Haemolytic anaemia has been reported rarely.
Undesirable effects reported of the individual components:
Hydrochlorothiazide(frequencies unknown):
Infections and infestations: sialoadenitis
Blood and lymphatic system disorders: leucopenia, neutropenia/agranulocytosis,
thrombocytopenia, aplastic anaemia, haemolytic anaemia, bone marrow depression.
Metabolism and nutrition disorders: anorexia, hyperglycaemia, glucosuria, hyperuricemia,
electrolyte imbalance (including hyponatraemia hypokalaemia, hypochloremic alkalosis and
hypomagnesaemia), increases in cholesterol and triglycerides gout.
Psychiatric disorders: restlessness, depression, sleep disturbance
Nervous system disorders: loss of appetite, paraesthesia, light-headedness
Eye disorders: xanthopsia, transient blurred vision
Ear and labyrinth disorders: vertigo
Cardiac disorders: Postural hypotension, cardiac arrhythmias
Vascular disorders: necrotising angiitis (vasculitis, cutaneous vasculitis)
Respiratory, thoracic and mediastinal disorders: respiratory distress (including pneumonitis
and pulmonatory oedema)
Gastrointestinal disorders: gastric irritation, diarrhoea, constipation, pancreatitis
Hepato-biliary disorders: jaundice (intrahepatic cholstatic jaundice)
Skin and subcutaneous disorders: photosensivity reactions, rash, cutaneous lupus
erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, urticaria,
anaphylactic reactions, toxic epidermal necrolysis
Musculoskeletal, connective tissue and bone disorders: muscle spasm, muscle weakness
Renal and urinary disorders: renal dysfunction, interstitial nephritis
General disorders: fever, weakness
Lisinopril and other ACE inhibitors:
Blood and the lymphatic system disorders:
rare: decreases in haemoglobin, decreases in haematocrit.
very rare: bone marrow depression, anaemia, thrombocytopenia, leucopenia, neutropenia,
agranulocytosis (see section 4.4), haemolytic anaemia, lymphadenopathy, autoimmune
disease
Metabolism and nutrition disorders:
very rare: hypoglycaemia
Nervous system and psychiatric disorders:
common: dizziness, headache, syncope
uncommon: mood alterations, paraesthesia, vertigo, taste disturbance, sleep disturbances.
rare: mental confusion
not known:
depressive symptoms

Cardiac and vascular disorders:
common: orthostatic effects (including orthostatic hypotension)
uncommon: myocardial infarction or cerebrovascular accident, possibly secondary to
excessive hypotension in high risk patients (see section 4.4), palpitations, tachycardia.
Raynaud’s phenomenon
not known:
flushing
Respiratory, thoracic and mediastinal disorders:
common: cough(see section 4.4)
uncommon: rhinitis
very rare: bronchospasm, sinusitis, allergic alveolitis /eosinophilic pneumonia
Gastrointestinal disorders:
common: diarrhoea, vomiting
uncommon: nausea, abdominal pain and indigestion
rare: dry mouth
very rare: pancreatitis, intestinal angioedema,
Hepatobiliary disorders:
uncommon:
elevated liver enzymes and bilirubin
very rare.
hepatitis- either hepatocellular or cholestatic, jaundice and hepatic failure (see
section 4.4)*
Skin and subcutaneous tissue disorders:
uncommon: rash, pruritus
rare: hypersensitivity/angioneurotic oedema: angioneurotic oedema of the face, extremities,
lips, tongue, glottis, and/or larynx (see section 4.4), urticaria, alopecia, psoriasis
very rare: diaphoresis, pemphigus, toxic epidermal necrolysis, Stevens-Johnson Syndrome,
erythema multiforme cutaneous pseudolymphoma**..

Renal and urinary disorders:
common: renal dysfunction
rare: uraemia, acute renal failure
very rare: oliguria/anuria
Reproductive system and breast disorders:
uncommon: impotence
rare: gynaecomastia
Endocrine disorders:
rare:

Syndrome of inappropriate antidiuretic hormone secretion (SIADH)

General disorders and administration site conditions:
uncommon: fatigue, asthenia
Investigations:
uncommon: increases in blood urea, increases in serum creatinine, increases in liver enzymes,
hyperkalaemia
rare:, hyponatraemia.
* Very rarely, it has been reported that in some patients the undesirable development of
hepatitis has progressed to hepatic failure. Patients receiving lisinopril-hydrochlorothiazide

combination who develop jaundice or marked elevations of hepatic enzymes should
discontinue lisinopril-hydrochlorothiazide combination and receive appropriate medical
follow up.
**A symptom complex has been reported which may include one or more of the following:
fever, vasculitis, myalgia, arthralgia/arthritis, a positive antinuclear antibodies (ANA),
elevated red blood cell sedimentation rate (ESR), eosinophilia and leucocytosis, rash,
photosensitivity or other dermatological manifestations may occur.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the Yellow
Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9

Overdose

There is no specific information available on the treatment of a lisinopril/hydrochlorothiazide
overdose. The treatment is symptomatic and supportive. Use of the medicinal product must
immediately be discontinued and the patient should be observed closely. Therapeutic
measures depend on the nature and severity of the symptoms. Measures should be taken to
prevent absorption and accelerate elimination. The recommended measures include inducing
vomiting and/or pumping the stomach if the drug was ingested recently, whereas dehydration,
disturbances of the electrolyte balance and hypotension should be treated in the usual manner.
Lisinopril
Limited data are available for overdose in humans. Symptoms associated with overdosage of
ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal
failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough.
The recommended treatment of overdose is intravenous infusion of normal saline solution. If
hypotension occurs, the patient should be placed in the shock position. If available, treatment
with angiotensin II infusion and/or intravenous catecholamines may also be considered. If
ingestion is recent, take measures aimed at eliminating lisinopril (e.g., emesis, gastric lavage,
administration of absorbents and sodium sulphate). Lisinopril may be removed from the
general circulation by haemodialysis (see section 4.4). Pacemaker therapy is indicated for
therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations
should be monitored frequently.
Hydrochlorothiazide
The most common objective and subjective signs and symptoms are the result of electrolyte
depletion (hypokalaemia, hypochloremia, hyponatraemia) and dehydration due to excessive
diuresis. Additional symptoms of hydrochlorothiazide overdose are increased diuresis,
depression of consciousness (incl. coma), convulsions, paresis, cardiac arrhythmias and renal
failure.
Bradycardia or extensive vagal reactions should be treated by administering atropine.
If digitalis has also been given, hypokalaemia may accentuate arrhythmia.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties

Pharmacotherapeutic group: ACE inhibitor (ACE: angiotensin converting enzyme)
and thiazide diuretic, ATC-code: C09B A03
Mechanism of action:
Both components, the ACE inhibitor and diuretic, have complementary modes of
action and exert an additive antihypertensive effect. ACE catalyses the conversion of
angiotension I to angiotension II, which has a strong vasoconstrictor effect and
stimulates aldosterone secretion. The antihypertensive effect of lisinopril is mainly
due to the suppression of the renin angiotensin-aldosterone system with reduction of
plasma concentration of angiotension II and aldosterone. Lisinopril exerts an
antihypertensive effect even in patients with low-renin hypertension. ACE is identical
to kininase II, an enzyme that degrades bradykinin. It remains unclear whether
increased levels of bradykinin (a potent vasodilator) plays a role in the therapeutic
effect of lisinopril.
Hydrochlorothiazide is a thiazide diuretic and an antihypertensive that increases the
plasma-renin activity. It suppresses the renal reabsorption of electrolytes in the renal
distal tubule and increases the excretion of sodium, chloride, potassium, magnesium,
bicarbonates and water. The excretion of calcium may be reduced. Concomitant
administration of lisinopril and hydrochlorothiazide gives a greater reduction in blood
pressure than monotherapy. Lisinopril normally attenuates the potassium loss
associated with hydrochlorothiazide.
The effects of the fixed dose combination of lisinopril and hydrochlorothiazide on
mortality and cardiovascular morbidity are currently unknown.
Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone
and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D
(The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the
combination of an ACE-inhibitor with an angiotensin II receptor blocker.
ONTARGET was a study conducted in patients with a history of cardiovascular or
cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of endorgan damage. VA NEPHRON-D was a study in patients with type 2 diabetes
mellitus and diabetic nephropathy.
These studies have shown no significant beneficial effect on renal and/or
cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia,
acute kidney injury and/or hypotension as compared to monotherapy was observed.
Given their similar pharmacodynamic properties, these results are also relevant for
other ACE-inhibitors and angiotensin II receptor blockers.
ACE-inhibitors and angiotensin II receptor blockers should therefore not be used
concomitantly in patients with diabetic nephropathy.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal
Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a
standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients
with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or
both. The study was terminated early because of an increased risk of adverse
outcomes. Cardiovascular death and stroke were both numerically more frequent in
the aliskiren group than in the placebo group and adverse events and serious adverse
events of interest (hyperkalaemia, hypotension and renal dysfunction) were more
frequently reported in the aliskiren group than in the placebo group.

5.2

Pharmacokinetic properties
The combined tablet is bioequivalent to monotherapy with each of the active
ingredients.

Absorption
Lisinopril: Approx 25%, with an interindividual variability of 6-60% on all the tested
dosages (5-80 mg). The absorption of lisinopril is not affected by food. Peak serum
concentrations are reached within 6-8 hours. Effect on blood pressure was observed
after 1-2 hours. The peak effect is obtained after 6 hours and lasts for at least 24
hours.
Hydrochlorothiazide: The diuretic effect is observed within 2 hours. The maximum
effect is attained after 4 hours. Clinically noticeable effect will last 6-12 hours.
Distribution
Protein binding: Lisinopril is not bound to plasma proteins except to ACE. A reduced
distribution volume may result in higher plasma concentrations in older patients than
in younger patients.
Half-life
Lisinopril: after multiple dosing 12 hours. Hydrochlorothiazide: 5½ - 15 hours.
Biotransformation /elimination
Both active components are excreted unchanged via the kidneys. Approx. 60% of the
orally administered hydrochlorothiazide is eliminated within 24 hours.

5.3

Preclinical safety data
Preclinical data reveal no special hazard for humans based on conventional studies of
safety pharmacology, repeated dose toxicology, genotoxicity and carcinogenic
potential. In animal tests ACE inhibitors induce adverse effects on the late fetal
development, resulting in fetal death and congenital effects, in particular affecting the
skull. Fetotoxity, intrauterine growth retardation and patent ductus arteriosus have
also been reported. These developmental anomalies are thought to be partly due to the
direct action of ACE inhibitors on the fetal renin-angiotensin system and partly due to
the ischaemia resulting from maternal hypotension and decreases in fetal-placental
blood flow and oxygen/nutrients delivery to the fetus (see 4.6).

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Calcium hydrogen phosphate anhydrous
Magnesium stearate
Pregelatinised starch
Mannitol
Maize starch.

6.2

Incompatibilities
Not applicable

6.3

Shelf life
2 years

6.4

Special precautions for storage
Do not store above 30°C.

6.5

Nature and contents of container
PVC/PVdC-aluminium blisters, packs of 14, 28, 30, 50, 98 and 100 tablets.
Hospital packs 50 (perforated unit dose blisters), 100.
Not all pack sizes may be marketed.

6.6

Special precautions for disposal
No special requirements

7

MARKETING AUTHORISATION HOLDER
Teva UK Limited
Brampton Road
Hampden Park
Eastbourne, East Sussex
BN22 9AG
United Kingdom

8

MARKETING AUTHORISATION NUMBER(S)
PL 00289/0456

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
8 July 2003

10

DATE OF REVISION OF THE TEXT
12/07/2017

+ Expand Transcript

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide